Plain-English translation of NCT06363825 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new combination approach for advanced liver cancer that includes a medication called , along with apatinib and two catheter-based procedures that deliver medicine directly to the liver. Researchers want to see if using these four treatments together is safe and effective for patients whose cancer has spread or grown significantly.
Currently, no studies have tested this specific four-drug combination for advanced liver cancer. If this treatment works well, it could offer patients a new option and help doctors design better treatments in the future.
You likely qualify if…
You likely don't qualify if…
If you join, you will receive a combination of treatments that includes medication taken by mouth or infusion, along with two procedures performed by specialists that deliver medicine directly into the blood vessels feeding your liver. You will attend regular clinic visits for monitoring, blood tests, and imaging scans to track how you are responding. The study involves close follow-up over several months to ensure the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fujian Medical University
Enrollment target
~57 participants
Started
April 2024
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in April 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yiping Chen
Nanping First Hospital of Fujian Province
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.